Mery Stéfani Leivas Pereira
Universidade Federal do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mery Stéfani Leivas Pereira.
PLOS ONE | 2012
Renata Leke; Diogo Losch de Oliveira; Ben Hur Marins Mussulini; Mery Stéfani Leivas Pereira; Vanessa Kazlauckas; Guilherme da Silva Mazzini; Carolina Rigatti Hartmann; Themis Reverbel da Silveira; Mette Simonsen; Lasse K. Bak; Helle S. Waagepetersen; Susanne Keiding; Arne Schousboe; Luis Valmor Cruz Portela
Hepatic encephalopathy (HE) arises from acute or chronic liver diseases and leads to several problems, including motor impairment. Animal models of chronic liver disease have extensively investigated the mechanisms of this disease. Impairment of locomotor activity has been described in different rat models. However, these studies are controversial and the majority has primarily analyzed activity parameters. Therefore, the aim of the present study was to evaluate locomotor and exploratory behavior in bile duct-ligated (BDL) rats to explore the spatial and temporal structure of behavior. Adult female Wistar rats underwent common bile duct ligation (BDL rats) or the manipulation of common bile duct without ligation (control rats). Six weeks after surgery, control and BDL rats underwent open-field, plus-maze and foot-fault behavioral tasks. The BDL rats developed chronic liver failure and exhibited a decrease in total distance traveled, increased total immobility time, smaller number of rearings, longer periods in the home base area and decreased percentage of time in the center zone of the arena, when compared to the control rats. Moreover, the performance of the BDL rats was not different from the control rats for the elevated plus-maze and foot-fault tasks. Therefore, the BDL rats demonstrated disturbed spontaneous locomotor and exploratory activities as a consequence of altered spatio-temporal organization of behavior.
European Journal of Pharmacology | 2009
André Prato Schmidt; Ana Elisa Böhmer; Cristhine Schallenberger; Catiele Antunes; Mery Stéfani Leivas Pereira; Renata Leke; Susana Tchernin Wofchuk; Elaine Elisabetsky; Diogo O. Souza
It is well known that adenine-based purines exert multiple effects on pain transmission. Recently, we have demonstrated that intracerebroventricular (i.c.v.) administered guanine-based purines are antinociceptive against chemical and thermal pain models in mice. The present study was designed to further investigate the antinociceptive effects of guanosine in mice. Animals received an intrathecal (i.t.) injection of vehicle (0.1 mN NaOH) or guanosine (10 to 400 nmol). Measurements of cerebrospinal fluid (CSF) purine levels and spinal cord glutamate uptake were performed. Guanosine produced dose-dependent antinociceptive effects against tail-flick, hot-plate, intraplantar (i.pl.) capsaicin, and i.pl. glutamate tests. Additionally, i.t. guanosine produced significant inhibition of the biting behavior induced by i.t. injection of glutamate (175 nmol/site), AMPA (135 pmol/site), kainate (110 pmol/site), trans-ACPD (50 nmol/site), and substance P (135 ng/site), with mean ID(50) values of 140 (103-190), 136 (100-185), 162 (133-196), 266 (153-461) and 28 (3-292) nmol, respectively. However, guanosine failed to affect the nociception induced by NMDA (450 pmol/site) and capsaicin (30 ng/site). Intrathecal administration of guanosine (200 nmol) induced an approximately 120-fold increase on CSF guanosine levels. Guanosine prevented the increase on spinal cord glutamate uptake induced by i.pl. capsaicin. This study provides new evidence on the mechanism of action of guanosine presenting antinociceptive effects at spinal sites. This effect seems to be at least partially associated with modulation of glutamatergic pathways by guanosine.
Oncotarget | 2017
Mery Stéfani Leivas Pereira; Fábio Klamt; Chairini Cássia Thomé; Paulo Valdeci Worm; Diogo Losch de Oliveira
Metabotropic glutamate receptors (mGluR) are predominantly involved in maintenance of cellular homeostasis of central nervous system. However, evidences have suggested other roles of mGluR in human tumors. Aberrant mGluR signaling has been shown to participate in transformation and maintenance of various cancer types, including malignant brain tumors. This review intends to summarize recent findings regarding the involvement of mGluR-mediated intracellular signaling pathways in progression, aggressiveness, and recurrence of malignant gliomas, mainly glioblastomas (GBM), highlighting the potential therapeutic applications of mGluR ligands. In addition to the growing number of studies reporting mGluR gene or protein expression in glioma samples (resections, lineages, and primary cultures), pharmacological blockade in vitro of mGluR1 and mGluR3 by selective ligands has been shown to be anti-proliferative and anti-migratory, decreasing activation of MAPK and PI3K pathways. In addition, mGluR3 antagonists promoted astroglial differentiation of GBM cells and also enabled cytotoxic action of temozolomide (TMZ). mGluR3-dependent TMZ toxicity was supported by increasing levels of MGMT transcripts through an intracellular signaling pathway that sequentially involves PI3K and NF-?B. Further, continuous pharmacological blockade of mGluR1 and mGluR3 have been shown to reduced growth of GBM tumor in two independent in vivo xenograft models. In parallel, low levels of mGluR3 mRNA in GBM resections may be a predictor for long survival rate of patients. Since several Phase I, II and III clinical trials are being performed using group I and II mGluR modulators, there is a strong scientifically-based rationale for testing mGluR antagonists as an adjuvant therapy for malignant brain tumors.
Neuroscience Bulletin | 2018
Thainá Garbino dos Santos; Mery Stéfani Leivas Pereira; Diogo Losch de Oliveira
Abstract Drugs that lack the ability to cross the blood-brain barrier (BBB) need to be placed directly into the central nervous system. Our laboratory studies the involvement of the glutamatergic system in the aggressiveness of glioma, and some ligands of glutamate receptors cannot permeate the BBB. Here, glioma-implanted rats were treated by a technique that delivers ligands directly into the cerebrospinal fluid by puncture into the cisterna cerebellomedullaris. Rats were anesthetized and fixed in a rodent stereotactic device. The head was gently tilted downwards at an angle that allowed exposure of the cisterna. Injection into the cisterna was done freehand using a gingival needle coupled to a microsyringe. The efficiency of intracisternal injection was demonstrated using a methylene blue solution. This type of injection is adaptable for any rodent model using small volumes of a variety of other drugs, and is an interesting method for neuroscience studies.
Brain Research | 2008
André Prato Schmidt; Ana Elisa Böhmer; Renata Leke; Cristhine Schallenberger; Catiele Antunes; Mery Stéfani Leivas Pereira; Susana Tchernin Wofchuk; Elaine Elisabetsky; Diogo O. Souza
Molecular Neurobiology | 2016
Felipe Schmitz; Paula Pierozan; André Felipe Rodrigues; Helena Biasibetti; Daniella de Moura Coelho; Ben Hur Marins Mussulini; Mery Stéfani Leivas Pereira; Mariana Migliorini Parisi; Florencia M. Barbé-Tuana; Diogo Losch de Oliveira; Carmen Regla Vargas; Angela Terezinha de Souza Wyse
Molecular Neurobiology | 2016
Samanta Oliveira Loureiro; Daniele Susana Volkart Sidegum; Helena Biasibetti; Mery Stéfani Leivas Pereira; Diogo Losch de Oliveira; Regina Pessoa-Pureur; Angela Terezinha de Souza Wyse
Neurochemical Research | 2014
Mery Stéfani Leivas Pereira; Kamila Cagliari Zenki; Marcela Mendonça Cavalheiro; Chairini Cássia Thomé; Eduardo Cremonese Filippi-Chiela; Guido Lenz; Diogo O. Souza; Diogo Losch de Oliveira
Archive | 2015
Mery Stéfani Leivas Pereira; Diogo Losch de Oliveira
Archive | 2014
Mery Stéfani Leivas Pereira; Diogo Losch de Oliveira